NCT07057089 - Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

December 1, 2030

Conditions

Locally Advanced Rectal Cancer

Interventions

DRUG

Capecitabine

Capecitabine: 825mg/m2, bid;

DRUG

Camrelizumab

Camrelizumab: 200mg

DRUG

CAPOX

RADIATION

Involve-field irradiation

Involve-field irradiation: Primary rectal tumor + metastatic or suspicious pelvic lymph nodes, mesorectal region, and presacral region

RADIATION

Elective nodal irradiation

Elective nodal irradiation: Large pelvic field

PROCEDURE

TME surgery

Trial Locations (1)

RECRUITING

the Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors

lead

Hebei Medical University Fourth Hospital

OTHER